Sensitivity analysis on a physiologically-based pharmacokinetic and pharmacodynamic model for diisopropylfluorophosphate-induced toxicity in mice and rats

被引:10
|
作者
Chen, Kaizhen [1 ]
Teo, Shiyi [1 ]
Seng, Kok -Yong [1 ]
机构
[1] DSO Natl Labs, Def Med & Environm Res Inst, Bioengn Lab, Singapore 117510, Singapore
关键词
Acetylcholinesterase; allometric scaling; diisopropylfluorophosphate; physiologically-based pharmacokinetic and pharmacodynamic model; sensitivity analysis; RISK-ASSESSMENT; INHIBITION; ACETYLCHOLINESTERASE; PLASMA; SOMAN; EXPOSURE; FORMS;
D O I
10.1080/15376510903300335
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
A physiologically-based pharmacokinetic and pharmacodynamic (PBPK/PD) model was recently developed to study the effect of diisopropylfluorophosphate (DFP) on acetylcholinesterase (AChE) activity in mouse and rat. That model takes into account relatively complex interactions involving many parameters, some of which may be uncertain and/or highly variable, especially those characterizing AChE activity after DFP intoxication. The primary objective of this study was to identify parameters that contribute most to the variability of AChE dynamics for model optimization against data. For this purpose, the influence of the variability of the rate constants for synthesis (K-syn) and degradation (K-deg) of AChE, and regeneration (K-reg) and aging (K-age) of inhibited AChE on the variability of AChE activity in mice and rat venous blood and brain was first calculated by a global sensitivity analysis. Next, the mouse PBPK/PD model was calibrated by optimizing the values of K-syn, K-deg, K-reg and K-age. Thereafter, scale-up of the DFP-induced AChE activity was performed from mouse to rat. Validation of the rat model was performed by comparing the time course of venous blood and brain AChE activities from a Monte Carlo analysis to those obtained in vivo. Sensitivity analysis on the verified models showed that K-reg and K-syn were the most influential factors of AChE activity at shorter and longer durations, respectively, after DFP challenge. Scale-up of the AChE dynamics from mouse to rat was also successful, as evidenced by significant overlapping between the predicted 95(th) percentile confidence intervals and the experimental data.
引用
收藏
页码:486 / 497
页数:12
相关论文
共 50 条
  • [21] Physiologically-based pharmacokinetic/pharmacodynamic modeling of meropenem in critically ill patients
    Yang, Yujie
    Wang, Yirong
    Zeng, Wei
    Zhou, Jinhua
    Xu, Min
    Lan, Ying
    Liu, Lvye
    Shen, Jian
    Zhang, Chuan
    He, Qin
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [22] A physiologically-based pharmacokinetic (PBPK) model of hydroxychloroquine
    Collins, Keagan P.
    Jackson, Kristen M.
    Gustafson, Daniel L.
    CANCER RESEARCH, 2017, 77
  • [23] The use of physiologically-based pharmacokinetic pharmacodynamic dosimetry models for chemical mixtures
    Yang, RSH
    ElMasri, HA
    Thomas, RS
    Constan, AA
    TOXICOLOGY LETTERS, 1995, 82-3 : 497 - 504
  • [24] Physiologically-based pharmacokinetic modeling of genistein in rats, part I: Model development
    Schlosser, PM
    Borghoff, SJ
    Coldham, NG
    David, JA
    Ghosh, SK
    RISK ANALYSIS, 2006, 26 (02) : 483 - 500
  • [25] Global sensitivity analysis in physiologically-based pharmacokinetic/pharmacodynamic models of inhaled and opioids anesthetics and its application to generate virtual populations
    Sanchez Restrepo, Frank
    Hernandez Valdivieso, Alher Mauricio
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2022, 49 (04) : 411 - 428
  • [26] Global sensitivity analysis in physiologically-based pharmacokinetic/pharmacodynamic models of inhaled and opioids anesthetics and its application to generate virtual populations
    Frank Sánchez Restrepo
    Alher Mauricio Hernández Valdivieso
    Journal of Pharmacokinetics and Pharmacodynamics, 2022, 49 : 411 - 428
  • [28] Sensitivity analysis of pharmacokinetic and pharmacodynamic systems: I. A structural approach to sensitivity analysis of physiologically based pharmacokinetic models
    Nestorov, IA
    JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1999, 27 (06): : 577 - 596
  • [29] LIMITING THE UNCERTAINTY IN RISK ASSESSMENT BY THE DEVELOPMENT OF PHYSIOLOGICALLY-BASED PHARMACOKINETIC AND PHARMACODYNAMIC MODELS
    FREDERICK, CB
    TOXICOLOGY LETTERS, 1993, 68 (1-2) : 159 - 175
  • [30] Sensitivity Analysis of Pharmacokinetic and Pharmacodynamic Systems: I. A Structural Approach to Sensitivity Analysis of Physiologically Based Pharmacokinetic Models
    Ivan A. Nestorov
    Journal of Pharmacokinetics and Biopharmaceutics, 1999, 27 : 577 - 596